LadRx Corp
DelistedCIK 799698fmd_11CR9W0S2ZPRGP73BJHD8Z0KBGManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Mar 31, 2025, 61 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | – | – | – | – | – | – |
| Research and development | 43 | 36 | 16 | 0 | 0 | 1 | – | – | 0 | 1 |
| Total operating expenses | – | – | 28 | 8 | 8 | 7 | 12 | 5 | 4 | 4 |
| Operating income | (63) | (52) | (28) | (8) | (8) | (7) | (12) | (5) | (4) | (4) |
| Interest expense | 0 | 3 | 4 | 2 | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | (0) | 0 | (0) | (0) | 0 | – |
| Income before taxes | (59) | (51) | (30) | (9) | (8) | (7) | (13) | – | – | – |
| Income tax expense | 0 | 0 | 0 | (0) | 0 | 0 | – | – | – | – |
| Net income from continuing operations | (59) | (51) | (30) | (9) | (8) | (7) | – | – | – | – |
| Net income | (59) | (51) | (35) | (13) | (7) | (7) | (13) | (4) | 0 | (2) |
| Net income to common shareholders | – | – | – | – | – | (7) | (13) | (5) | 0 | (2) |